Niaspan buyers denied class cert
A federal judge in Pennsylvania has rejected a bid for class certification by end-purchasers of cholesterol medication Niaspan in their lawsuit against drugmakers AbbVie and Teva Pharmaceuticals.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10